SCHEMBL4597267

SCHEMBL4597267

O=C1Nc2ccccc2C1(O)c1ccc2c(c1)OCO2

nearest known ligand 0.57

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.55
CASP6 P55212 1/20 0.55
SCN9A Q15858 16/20 0.53
MTOR P42345 1/20 0.52
RICTOR Q6R327 1/20 0.52
RPTOR Q8N122 1/20 0.52
MAPKAP1 Q9BPZ7 1/20 0.52
MLST8 Q9BVC4 1/20 0.52
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2500895 0.83 SCN9A (0.50) POLBCASP6SCN9AMEN1KMT2A
SCHEMBL1612096 0.81 KMT2A (0.63) POLBCASP6MTORRICTORRPTOR
SCHEMBL4730463 0.78 SCN9A (0.45) SCN9A
SCHEMBL7314592 0.77 SLC6A3 (0.54) SCN9A
SCHEMBL24281054 0.74 POLB (0.77) POLBCASP6MEN1KMT2A
SCHEMBL31306897 0.74 KMT2A (0.66) POLBCASP6MEN1KMT2A
SCHEMBL209276 0.74 KMT2A (0.66) POLBCASP6MEN1KMT2A
SCHEMBL18025761 0.74 KMT2A (0.66) POLBCASP6MEN1KMT2A
SCHEMBL18552443 0.74 KMT2A (0.66) POLBCASP6MEN1KMT2A
SCHEMBL16108033 0.74 BRD4 (0.73)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101213174-A Oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2008-07-02 CN claimed
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2007-05-10 US claimed
CN-101213174-A Oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2008-07-02 CN disclosed
WO-2008046083-A2 USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-04-17 WO disclosed
EP-1877378-A2 OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-01-16 EP disclosed
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2007-05-10 US disclosed
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2007-05-10 US disclosed
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2007-05-10 US disclosed
WO-2006113864-A2 OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents OPRL1, OPRK1, TRPV1 POLB 4840/4885CASP6 3308/4885SCN9A 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.